Sign up USA
Proactive Investors - Run By Investors For Investors

Rigel Pharmaceuticals' price target is raised to US$7 by Jefferies analyst

Shares popped higher after the FDA approved its new drug application for Fostamatinib, known by brand name Tavalisse
Picture of pills
Eun Yang of Jefferies sees the approval of Tavalisse as a 'transformational' event

The share price target for Rigel Pharmaceuticals (NASDAQ:RIGL) has been raised to US$7 from US$5 by Eun Yang, a Jefferies analyst, following the US Food and Drug Administration’s approval of Rigel’s drug for a rare bleeding disorder.

Yang sees the approval this week of Tavalisse as a “transformational” event for Rigel and is keeping a 'Buy' rating on the stock, according to a note obtained by, a business news website.

The analyst puts a peak sales estimate of US$190mln on the drug which has been approved to treat patients with immune thrombocytopenic purpura, a disease which results in extensive bruising and bleeding due to low blood platelet levels.

Read: Rigel Pharmaceuticals gets FDA approval for treatment of rare bleeding disorder

The drug can also be used to treat second indication autoimmune hemolytic anaemia, which will likely be a “further driver of valuation”, according to Yang

Shares in Rigel have gained ground since Tuesday when the FDA approved the company’s new drug application for its lead drug Fostamatinib, which is known by its brand name Tavalisse.

The shares continued to rise in pre-market action but eased up to add only about 1% to US$4.17 in the regular session.

View full RIGL profile View Profile

Rigel Pharmaceuticals Timeline

Related Articles

scientist in lab
August 31 2018
While the data bodes well for MTD201, Midatech is most excited by the validation of its Q-Sphera sustained release technology, which it is using in some of its other compounds
Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
picture of cannabis plants
March 23 2018
Control of the supply chain offers operational advantages and financial benefits.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use